FDA approves valve treated to prevent calcification

The FDA approved a bioprosthetic heart valve that is treated to improve durability.

The Italian company Sorin Group announced that it received FDA approval for its Mitroflow Aortic Pericardial Heart Valve with Phospholipid Reduction Treatment. The treatment extracts phospholipids from pericardial tissue. Phospholipids have been linked to the calcification process of bioprotheses, which affects durability. In animal models, the treatment process reduced calcium uptake compared with a control.

Mitroflow with Phospholipid Reduction Treatment received CE mark on July 28, 2011.

Candace Stuart, Contributor

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup